PREMS Biomedical AI Advances AI-Enhanced Smart Sleeve for Neuromuscular Rehabilitation
FORT LAUDERDALE, FL / ACCESS Newswire / October 5, 2026 / PREMS Biomedical AI LLC has designed an AI-enhanced wearable rehabilitation platform designed to sense a user's muscle activity and respond with proportional electrical stimulation in real time.
Built around the concept of "amplifying neural effort," the PREMS smart sleeve combines surface electromyography (sEMG) sensing, electrical muscle stimulation and AI-based adaptive control. The system is being designed for home-based daily use with connected monitoring for clinicians.
PREMS.AI identifies potential applications including stroke rehabilitation, spinal cord injury, traumatic brain injury, Parkinson's disease, post-operative rehabilitation and sports injury recovery.
The technology builds on proportional-response intellectual property associated with U.S. Patent 4,811,742. The company also cites existing FDA 510(k) K874212, associated with VERIMED MYO/PREMS, as a predicate in its strategy for pursuing a new 510(k). A Provisional Patent is now filed for PREMS Biomedical AI.
PREMS.AI is currently described in its materials as pre-revenue and seed stage, with development priorities spanning hardware, AI, clinical validation and regulatory activities.
About PREMS Biomedical AI LLC
PREMS.AI Biomedical is a Fort Lauderdale-based biomedical technology company.
Media Contact
William W. Mee
Founder & CTO, PREMS Biomedical AI LLC
[email protected]
Fort Lauderdale, Florida
(954) 648-6020
SOURCE: PREMS Biomedical AI LLC
View the original press release on ACCESS Newswire
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fortitude Gold Declares October 2026 Monthly Dividend
- Cubic Appoints Elliot "Lee" Sander President and Chief Executive Officer of Cubic Transportation Systems
- TMX Group Thanksgiving Holiday Market Closures
Create E-mail Alert Related Categories
ACCESS Newswire, Press ReleasesRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share